ProFACT forms collaborations with Cancer therapeutics and diagnostics developers, offering an advantaged Proteomic Profiling strategy in the SeraFILE™ profiling applications platform and an early stage commercialization pathway.

Collaborations are structured as partnerships or joint ventures with research institutions and Biopharmaceutical companies. As projects move closer to commercial status, they can be licensed on, sold off or retained by ProFACT for further value-addition and commercialization.